Rapid Synthesis of Plasmids and Mutagensis - JCVI
Past New Requirement Updated
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Solicitation expected
- Not on record
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- Lindsay Culp lvc9@cdc.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) is forecasting a contract renewal for Rapid Synthesis of Plasmids and Mutagenesis through the Joint Technology Center for Immunology (JCVI). The contract, originally awarded in Q4 of FY23, is estimated for award on February 1, 2025, with minimal detailed information currently available. The opportunity is not set aside for any specific small business category, suggesting open competition.
While specific award values and precise contract details are not disclosed, the forecast indicates this is a renewal contract within the National Center for Immunization and Respiratory Diseases (NCIRD). The primary point of contact is Lindsay Culp, reachable at lvc9@cdc.gov, who is associated with the CDC's NCIRD division. Due to the limited information provided, potential vendors should anticipate reaching out directly to Lindsay Culp for more comprehensive contract specifications and requirements.
Forecast text
Renewal of contract awarded in Q4 of FY23, so detailed information is unavailable.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast